Xenon pauses phase 3 depression trials after psychosis events
Xenon Pharmaceuticals suspended enrollment in segments of its late-stage psychiatry studies to evaluate adjustments aimed at enhancing tolerability after receiving reports of psychosis events. This pause impacted major depressive disorder and bipolar disorder trials, resulting in a single-day market value drop of nearly a third. Concurrently, the company submitted its first new drug application for azetukalner to treat focal-onset seizures. The neurology pipeline continues to advance while psychiatric safety signals drive investor volatility and subsequent legal scrutiny.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Xenon Pharmaceuticals filed its first new drug application for azetukalner as a treatment for focal-onset seizures.
- ✓ The company paused portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability following psychosis events.
- ✓ A single adverse-event disclosure erased nearly a third of Xenon's market value in a day.
What changed
Xenon officially filed its first new drug application for azetukalner while detailing that the psychiatry trial pauses are intended to evaluate tolerability modifications.
Live updates
-
Xenon Pauses Psychiatry Trials While Filing Azetukalner NDA
Xenon Pharmaceuticals suspended enrollment in segments of its late-stage psychiatry studies to evaluate adjustments aimed at enhancing tolerability after receiving reports of psychosis events. This pause impacted major depressive disorder and bipolar disorder trials, resulting in a single-day market value drop of nearly a third. Concurrently, the company submitted its first new drug application for azetukalner to treat focal-onset seizures. The neurology pipeline continues to advance while psychiatric safety signals drive investor volatility and subsequent legal scrutiny.
Why it matters
The dual developments highlight the tension between Xenon's core epilepsy franchise and its expansion into neuropsychiatric indications. While the submission for azetukalner moves the focal seizure treatment closer to commercialization, psychiatric side effects have immediately threatened market valuation. The contrast underscores how critical safety events in early- or late-stage trials can overshadow broader regulatory progress for diversified biotech firms.
What is confirmed
- Xenon Pharmaceuticals filed its first new drug application for azetukalner as a treatment for focal-onset seizures.
- The company paused portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability following psychosis events.
- A single adverse-event disclosure erased nearly a third of Xenon's market value in a day.
Still unconfirmed
- SueWallSt issued an investigation notice regarding the psychiatry trial pause and stock decline.
What to watch next
- FDA decisions regarding the new drug application for azetukalner
- Updates on protocol changes intended to improve tolerability in psychiatry trials
- Further developments from the SueWallSt investigation notice
confidence 100%Sources used for this update (2)
- finance.biggo.com — Xenon's 30% Plunge Hides an Epilepsy Moat, Says Biotech Hangout's Paul Matteis
- finance.yahoo.com — Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials ...
-
Xenon stock drops after pausing Phase 3 depression trials
Xenon Pharmaceuticals paused new enrollment in Phase 3 clinical trials for major depressive disorder and bipolar disorder following psychosis events. The company's stock price fell 31% to $40 as of September 19. This pause coincided with the September 17 submission of a New Drug Application to the FDA for azetukalner, a focal seizure treatment. While the epilepsy program is advancing, the neuropsychiatric side effects in the psychiatry studies have caused significant investor volatility and a subsequent investigation notice from SueWallSt.
Why it matters
The company is attempting to balance a regulatory push for an epilepsy drug with safety failures in its psychiatric pipeline. Investors are weighing the potential FDA approval of azetukalner against the instability of the depression trials. A stock price target for the company currently sits at $78.
What is confirmed
- Xenon Pharmaceuticals paused enrollment in Phase 3 studies for bipolar disorder and major depressive disorder.
- The company submitted a New Drug Application to the U.S. FDA on September 17 for an epilepsy treatment.
- Xenon stock price was $40 as of September 19.
- The stock price declined 31% following the study pause.
Still unconfirmed
- SueWallSt is conducting an investigation into Xenon Pharmaceuticals.
What to watch next
- FDA decision on the azetukalner New Drug Application
- Results of the safety review regarding psychosis events in depression trials
- Outcome of the SueWallSt investor investigation
confidence 95%Sources used for this update (3)
- finance.yahoo.com — Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
- www.prnewswire.com — Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
- www.insidermonkey.com — Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
-
Xenon Pauses Phase 3 Depression Trials Over Psychosis Events
Xenon Pharmaceuticals has voluntarily paused new enrollment in its Phase 3 clinical trials for bipolar depression and major depressive disorder. The company halted the studies following neuropsychiatric side effects, specifically psychosis events. This setback occurred the same day Xenon submitted a New Drug Application to the FDA for azetukalner, a drug intended to treat focal seizures. Despite the regulatory filing for its epilepsy treatment, Xenon shares fell between 30% and 32.2% as investors reacted to the psychiatry program's instability.
Why it matters
Phase 3 trials are the final stage of testing before a drug can be approved for public use. A pause due to safety concerns can delay market entry or lead to total program termination. The company is currently balancing this setback against the potential approval of its focal seizure medication.
What is confirmed
- Xenon paused new enrollment in Phase 3 trials for major depressive disorder and bipolar depression.
- The trial pause follows reports of psychosis events and neuropsychiatric side effects.
- Xenon submitted a New Drug Application to the FDA for azetukalner to treat focal seizures.
- Xenon stock prices dropped by approximately 30% following the trial pause.
What to watch next
- FDA decision on the azetukalner NDA for focal seizures
- Xenon announcement on whether the depression trials will resume or be terminated
- Detailed safety data release regarding the neuropsychiatric events
confidence 100%Sources used for this update (8)
- Fierce Biotech — Xenon pauses phase 3 depression trials after psychosis events
- Reuters — Xenon pauses new enrollment in depression drug trials over side-effect concerns
- Yahoo Finance — XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
- Barron's — Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
- Investor's Business Daily — Why This Biotech Just Erased Its One-Day 50% Pop
- Yahoo Finance — Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
- BioPharma Dive — Xenon shares fall following depression trial pause
- finance.yahoo.com — Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community